Avanzarx Pharmaceutical Holdings, LLC

Name of License: Avanzarx Pharmaceutical Holdings, LLC

Laboratory:

On: Jul 22, 2021

Summary:

VA intends to offer Avanzarx Pharmaceutical Holdings, LLC an exclusive license to technology called "Treatment of Pulmonary Fibrosis using NEU1 Salidase Inhibitors" by Goldblum et al., VA ID 2019-175

Tech Name: Treatment of Pulmonary Fibrosis using NEU1 Salidase Inhibitors

Action: Intent

Dates: July 22, 2021 through August 6, 2021

Address: U.S. Department of Veterans Affairs Technology Transfer Program (14RDTT) 810 Vermont Ave, NW Washington, DC 20420

For Further Information Contact:

David Marks
U.S. Department of Veterans Affairs
Technology Transfer Program (14RDTT)
810 Vermont Ave, NW
Washington, DC 20420
Office: 202-443-5609
email: [email protected]